Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
Xconomy
JANUARY 25, 2019
After guiding the CRISPR-Cas9 genome-editing startup from scientific breakthrough toward the development of a potential cutting-edge medicine, slogging victoriously through a legendary patent fight , and reaching the cusp of an historic clinical trial , the well-traveled Bosley is cutting out, the company said Tuesday.
63 
Let's personalize your content